Business Wire

Ultivue Announces $50M Financing Round

Share

Ultivue, a leader in advancing precision medicine solutions through a unique approach that combines multiplex biomarker analysis with same slide traditional H&E for tissue phenotyping, today announced the completion of a $50 million Series D round of financing. New investors include Ally Bridge Group, Pura Vida Investments and Tao Capital Partners. Previous venture investors in Ultivue who also participated in the financing include ARCH Ventures, Northpond Ventures and Applied Ventures, LLC.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210427005387/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Multiplexed immunofluorescence image depicting immune infiltrates in a non-small cell lung cancer (NSCLC) sample. (Photo: Business Wire)

This additional funding will help Ultivue strengthen its position in the market, deliver innovative solutions to address the dynamic nature of tumor biology from precious tissue samples and to provide researchers and pathologists with the ability to fully realize the potential of tissue biomarkers within digital pathology workflows.

Anna Yaeger, President and Portfolio Manager commented, "Ally Bridge Group is excited to be long term partners with Ultivue. We believe the company's differentiated kit-based approach to multiplex immunofluorescence is well positioned to capitalize on the spatial biology revolution and creates maximum flexibility to support academic, biopharma, and CRO customers."

“What Ultivue has is remarkably capable. They provide fast, accurate, previously unattainable multiplexed protein marker information at high resolution and on existing hardware. It is going to be exciting to see a well-resourced, well led Ultivue offer great capabilities to the biotech and pharma oncology community,” said Keith Crandell, Co-founder & Managing Director from ARCH Ventures.

“Ultivue is driving to make immunotherapy a reality for every patient that needs it with leading technology that enables advanced exploration and interrogation of tissue samples for precision medicine research. We’re proud to continue supporting the Ultivue team,” said Adam Wieschhaus, Ph.D., CFA, Director at Northpond Ventures.

“We’re excited to welcome our newest investors, and greatly appreciate the support from our existing investment partners,” says Jacques Corriveau, President and CEO of Ultivue. “This funding will allow us to expand our commercial efforts while also increasing the scope of our research and development in order to remain at the forefront of innovation and provide biological insights for our customers as they work to address the challenge of therapeutic response rates in patients using immunotherapy.”

About Ultivue:

Ultivue provides researchers and scientists with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions and scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mark Rees
Ultivue
mark.rees@ultivue.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SentinelOne Receives Highest Score for Type B Use Case in the Gartner 2021 Critical Capabilities for Endpoint Protection Platforms13.5.2021 16:00:00 CEST | Press release

SentinelOne, the autonomous cybersecurity platform company, today announced that Gartner has positioned SentinelOne with the highest score in use case Type B in Gartner’s 2021 Critical Capabilities for Endpoint Protection Platforms report1. SentinelOne received the highest score for all three customer types out of 19 vendors. Gartner says, “Type B organizations aim to stay relatively current on technology without getting too far ahead or behind their competition.” “We believe receiving the highest product score among organizations prioritizing overall value in the 2021 Critical Capabilities for Endpoint Protection Platforms validates our vision and execution in delivering an AI-powered platform purpose built for the demands of the mainstream enterprise market,” said Raj Rajamani, Chief Product Officer, SentinelOne. “These organizations represent the largest market segment out of Gartner’s use cases and prioritize technology deployments that improve their organization’s productivity, pr

Wipro Has Earned the Microsoft Windows Virtual Desktop Advanced Specialization13.5.2021 15:12:00 CEST | Press release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today said it has earned the Microsoft Windows Virtual Desktop advanced specialization, a validation of a partner’s deep knowledge, extensive experience and expertise in deploying, scaling and securing virtual desktop infrastructure on Azure. Only partners that meet stringent criteria around customer success and staff skilling, as well as pass a third-party audit of their Windows Virtual Desktop technical practices are able to earn the Microsoft Windows Virtual Desktop advanced specialization. Supporting secure remote work for employees is more critical than ever. Windows Virtual Desktop is a Microsoft solution that seamlessly integrates with other Microsoft products and allows customers to implement virtual desktops in a scalable, secure, and cost-effective way. Partners with validated capabilities in implementing Windows Virtual Desktop can he

Schlumberger Appoints Dr. Katharina Beumelburg as Chief Strategy and Sustainability Officer13.5.2021 15:00:00 CEST | Press release

Schlumberger announced today the appointment of Dr. Katharina Beumelburg to the position of Chief Strategy and Sustainability Officer, Schlumberger Limited, reporting to Olivier Le Peuch, Chief Executive Officer. The appointment is effective Monday, May 17. As a member of the executive team, Dr. Beumelburg will oversee corporate strategy, sustainability, marketing and communications activities across the Company. Dr. Beumelburg joins Schlumberger from a global technology company, Siemens, where she has held various leadership positions including strategy development incorporating sustainability; management consulting; business excellence; and operations management. In her most recent position, she led the global Transmission Services business. “I am delighted to welcome Katharina to the Schlumberger team at a pivotal time for the company, the energy industry and our planet. Sustainability is increasingly core to our performance strategy, through which we will realize our vision,” said

Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week ® (DDW) 202113.5.2021 14:00:00 CEST | Press release

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced that Phase 3 data evaluating its investigational microbiota-based live biotherapeutic RBX2660 for reduction of recurrent Clostridioides difficile(C. difficile) infection will be presented as part of an invited talk at Digestive Disease Week® (DDW) 2021. The congress will take place virtually from May 21-23, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210513005129/en/ “These data are the pinnacle of a decade of ground-breaking research and development, driven by the goal of helping those who are experiencing the debilitating effects of recurrent C. difficile infection,” said Lee Jones, Founder, President and Chief Executive Officer of Rebiotix, a Ferring Company. “We’re striving to deliver innovative therapeutics to help people live better lives, and are proud to be pioneering a new category of scientifically-validated, microbiome-based therapeu

S&P Global Ratings Recognizes PMI’s Business Transformation as Industry Differentiator13.5.2021 13:59:00 CEST | Press release

Philip Morris International Inc. (PMI) (NYSE:PM) is transforming its business to deliver a smoke-free and sustainable future. Today, the company announced that S&P Global Ratings’ ESG Evaluation report has assessed PMI’s approach to environmental, social, and governance (ESG) topics and confirmed that PMI has positively differentiated itself within the tobacco sector. The S&P Global Ratings ESG evaluation assesses a company’s ESG strategy and ability to prepare for potential future risks and opportunities, and provides a forward-looking, long-term opinion of a company’s readiness for disruptive ESG risks and opportunities. It provides an overall score that allows comparison with other entities globally, including sector peers, and consists of a combined sector/region score, an entity-specific score, and a preparedness score. Based on entity-specific scores — designed to indicate how a company is actively and effectively managing its exposure to ESG risks and opportunities compared with

Genius Sports to Announce First Quarter 2021 Results on May 2013.5.2021 13:00:00 CEST | Press release

Genius Sports Limited (NYSE:GENI) (“Genius” or “GSL”) today announced that it will release its first quarter 2021 results before 8:00AM EDT on Thursday, May 20, 2021. At 8:00AM EDT on the same day, Genius will host a conference call to discuss the results. Genius’ earnings press release and related materials will be available at investors.geniussports.com. To listen to the live audio webcast and Q&A, please visit Genius’ investor relations website at investors.geniussports.com. A replay of the webcast will be available on the website within 24 hours after the call. About Genius Sports Genius Sports is the official data, technology and commercial partner that powers the global ecosystem connecting sports, betting and media. We are a global leader in digital sports content, technology and integrity services. Our technology is used in over 150 countries worldwide, empowering sports to capture, manage and distribute their live data and video, driving their digital transformation and enhanc

Knopp Biosciences to Present Details of Positive Results From the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 202113.5.2021 12:00:00 CEST | Press release

Knopp Biosciences LLC today announced it will present detailed results of its positive Phase 2 dose-ranging EXHALE trial of the novel oral eosinophil-lowering drug dexpramipexole in patients with moderate-to-severe asthma in a virtual poster session at the ATS 2021 International Conference. “We look forward to sharing comprehensive results of the EXHALE trial, which underscore the readiness of dexpramipexole for further development in eosinophilic asthma,” said Michael Bozik, M.D., president and CEO of Knopp. “Monoclonal antibody treatments approved for asthma demonstrate that reduction in eosinophils is associated with significantly improved outcomes, but the need remains for an oral alternative in the eosinophilic asthma treatment paradigm.” Following are details of the poster presentation: Poster Title Abstract Number / Presentation Details Oral Dexpramipexole Efficacy in Lowering Blood Eosinophils in Patients with Moderate to Severe Uncontrolled Eosinophilic Asthma A1359 Poster Pre